Fallah Hossein, Akbari Hamed, Abolhassani Moslem, Mohammadi Abbas, Gholamhosseinian Ahmad
Department of Biochemistry, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Endocrinology and Metabolism Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran.
Iran J Basic Med Sci. 2017 Oct;20(10):1093-1101. doi: 10.22038/IJBMS.2017.9409.
This study was aimed to investigate the effect of extract on insulin sensitivity in high-fructose-fed insulin-resistant rats.
Experimental rats were randomly divided into two groups: the control group was fed a regular chow diet while other group fed with a high-fructose diet for 8 weeks. After the first six weeks, the animals were treated with extract or pioglitazone for two weeks. Insulin and adiponectin levels were measured by ELISA. Additionally, Insulin resistance was calculated using a Homeostasis Model Assessment of Insulin resistance (HOMA-IR). The plasma free fatty acid (FFA) profile was obtained by gas chromatography. PPARγ and GLUT4 gene expression were assessed by real-time polymerase chain reaction (PCR) and western-blotting.
Comparing the treated group with the control group, weight gain (=0.009) and levels of insulin (=0.001), blood glucose (<0.0001), and HOMA-IR (<0.0001) were significantly reduced. Additionally, the adiponectin concentration was significantly increased (<0.0001). Among the FFA fractions, the mean concentration of palmitoleic acid and stearic acid in the group were significantly higher than the control group (<0.0001 and =0.005, respectively). However, there was no significant difference at the mRNA and protein level of GLUT4 and PPAR-γ between B. treated group and control group.
The study findings revealed that might be a protective candidate against Type 2 diabetes/insulin resistance through direct insulin-like effect and an increase in adiponectin levels. However, the mechanism of was independent of GLUT4 and PPARγ.
本研究旨在探讨提取物对高糖喂养的胰岛素抵抗大鼠胰岛素敏感性的影响。
将实验大鼠随机分为两组：对照组给予常规饲料，另一组给予高糖饲料8周。在前六周后，动物用提取物或吡格列酮处理两周。通过酶联免疫吸附测定法（ELISA）测量胰岛素和脂联素水平。此外，使用胰岛素抵抗稳态模型评估（HOMA-IR）计算胰岛素抵抗。通过气相色谱法获得血浆游离脂肪酸（FFA）谱。通过实时聚合酶链反应（PCR）和蛋白质免疫印迹法评估PPARγ和GLUT4基因表达。
与对照组相比，提取物处理组的体重增加（P = 0.009）、胰岛素水平（P = 0.001）、血糖（P < 0.0001）和HOMA-IR（P < 0.0001）显著降低。此外，脂联素浓度显著增加（P < 0.0001）。在FFA组分中，提取物组的棕榈油酸和硬脂酸平均浓度显著高于对照组（分别为P < 0.0001和P = 0.005）。然而，提取物处理组和对照组之间GLUT4和PPAR-γ的mRNA和蛋白质水平没有显著差异。
研究结果表明，提取物可能通过直接的胰岛素样作用和脂联素水平的增加成为2型糖尿病/胰岛素抵抗的保护性候选物。然而，提取物的作用机制独立于GLUT4和PPARγ。
